MedPointe Bringing Optivar Promotion In-House Starting In January
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will end its co-promotion agreement with Bausch & Lomb for azelastine ophthalmic solution at year-end. MedPointe added 17 new allergy specialty reps in the quarter to detail the conjunctivitis agent.
You may also be interested in...
B&L Will Shift Optivar Reps To Anticipated New Product Launches In 2005
Reps will support projected launches for ZyLET and Retisert following the end of a co-promotion agreement for MedPointe's Optivar. B&L expects action on the ZyLET NDA next year and on the Retisert application by year-end.
B&L Will Shift Optivar Reps To Anticipated New Product Launches In 2005
Reps will support projected launches for ZyLET and Retisert following the end of a co-promotion agreement for MedPointe's Optivar. B&L expects action on the ZyLET NDA next year and on the Retisert application by year-end.
Sepracor, MedPointe To End Astelin Co-Promotion Agreement
The companies will continue to detail the product until June 30, then Sepracor will be responsible for sample coverage until the end of the year. Sepracor plans to focus sales efforts on in-house products.